ライフサイエンスコーパス: BCG

1 BCG appears to reduce acquisition of Mycobacterium tuber

2 BCG complemented with M. tuberculosis ppe37 exhibits HIA

3 BCG induced potent quantities of IL-6 and IL-10, and the

4 BCG infection increased expression of CD54, MHC Class I

5 BCG is associated with lower prevalence of LTBI in adult

6 BCG is the most effective therapy for high-risk non-musc

7 BCG led to short-term and long-term potentiation of mono

8 BCG protection decreased with increasing exposure (P = .

9 BCG revaccination transiently expanded peripheral blood

10 BCG vaccination clinical trials are required to corrobor

11 BCG vaccination did not alter levels of antibodies again

12 BCG vaccination has been demonstrated to increase levels

13 BCG vaccination has beneficial nonspecific (heterologous

14 BCG vaccination has recently been proposed as a strategy

15 BCG vaccination leads to changes in IFN-gamma responsive

16 BCG vaccination reduced the risk of a positive baseline

17 BCG vaccination significantly enhanced the ability of IN

18 BCG vaccination tended to reduce neonatal and infant sep

19 BCG was also associated with an altered immune gene expr

20 BCG-Denmark and BCG-Japan induced more BCG scars and PPD

21 BCG-Denmark and BCG-Japan were more immunogenic than BCG

22 BCG-disA-OE elicited significantly stronger tumor necros

23 BCG-induced changes in other cytokine responses to heter

24 BCG-vaccinated infants also had increased production of

25 achieved M. tuberculosis detection at 10(1) BCG cells/ml, with 31 to 59 M. tuberculosis complex read

26 We analyzed 233 BCG adverse reactions, namely regional lymphadenitis (33

27 ; >91% coverage (1x depth) occurred at 10(3) BCG cells/ml.

28 overage (>97% at 5x depth) occurred at 10(4) BCG cells/ml; >91% coverage (1x depth) occurred at 10(3)

29 there were 908 infant hospitalizations (450 BCG, 458 controls) and 135 in-hospital deaths (56 BCG, 7

30 458 controls) and 135 in-hospital deaths (56 BCG, 79 controls).

31 k/BCG-Russia (MRR, 1.15 [95% CI, .74-1.80]); BCG-Japan/BCG-Russia (MRR, 0.71 [95% CI, .43-1.19]).

32 A BCG growth inhibitor, 2-thiophenecarboxylic acid hydrazi

33 the ID93/GLA-SE vaccine candidate given as a BCG-prime boost regimen confers a high level of long-ter

34 tive efficacy of ID93/GLA-SE as a boost to a BCG-prime against the hypervirulent Mycobacterium tuberc

35 Accordingly, BCG-induced tumor elimination and tumor-specific immune

36 erculosis mortality benefit of administering BCG on time and consequences of later administration.

37 to investigate the immunogenicity of aerosol BCG vaccination, and the phenotypic profile of periphera

38 ating inflammatory proteins before and after BCG vaccination, while ex vivo Mycobacterium tuberculosi

39 predominance of the Beijing genotype, after BCG vaccination.

40 cytokine responses (trained immunity) after BCG vaccination.CONCLUSIONThe capacity of BCG to enhance

41 Six months after BCG vaccination, macaques were challenged with virulent

42 ell and monocyte activation that occur after BCG vaccination but do not support the hypothesis that B

43 ctions might occur more than two years after BCG inoculation and the policy of delayed BCG inoculatio

44 fore, as well as 2 weeks and 3 months after, BCG vaccination.

45 tion could be further improved by the Mtb Ag/BCG IFNgamma ratio (p < 0.0001 AUC = 0.91).

46 orrelation between incidence of COVID-19 and BCG vaccination policies.

47 BCG-Denmark and BCG-Japan induced more BCG scars and PPD reactions than

48 BCG-Denmark and BCG-Japan were more immunogenic than BCG-Russia by the m

49 ong neonates vaccinated with BCG-Denmark and BCG-Russia, respectively (IRR, 1.08 [95% confidence inte

50 vestigated the effects of M.tb infection and BCG vaccination on B cell responses to heterologous path

51 or patients with intermediate-risk NMIBC and BCG-unresponsive NMIBC.

52 The optimal PPD and BCG dose was 0.5 TU and 10(4) cfu, respectively, based o

53 s (Mtb) ESX-1 secretion system (BCG::RD1 and BCG::RD1 ESAT-6 Delta92-95) are safe and confer superior

54 nses is induced by vaccination with Tdap and BCG, and more studies are warranted to investigate wheth

55 the effectiveness of preventive therapy and BCG vaccination on the risk of developing tuberculosis.

56 by comparing left and right swing times, and BCG was assessed by the phase coordination index (PCI).

57 or the first 2 weeks in unimmunized animals, BCG promotes the accelerated recruitment and infection o

58 The effects of age at BCG and time since vaccination were also explored.

59 vities are sufficient to restrict attenuated BCG, but not virulent wild-type M. bovis or M. tuberculo

60 ily activities, the limb ballistocardiogram (BCG) is receiving an increasing interest as a viable mea

61 subtle respiration and ballistocardiograph (BCG) monitoring.

62 es.METHODSWe investigated the impact of BCG (BCG-Bulgaria, InterVax) vaccination on systemic inflamma

63 recombinant Bacillus Calmette-Guerin ([BCG] BCG-disA-OE) that overexpresses the endogenous mycobacte

64 nts with mild MS showed significantly better BCG as reflected by lower PCI values in comparison to th

65 as strong evidence of an association between BCG and LTBI (adjusted odds ratio = 0.70; 95% confidence

66 he null hypothesis of no association between BCG vaccination and COVID-19 mortality, and suggest that

67 ting rates, there was no association between BCG vaccination policy and COVD-19 spread rate or percen

68 ted here, and to establish causality between BCG vaccination and protection from severe COVID-19.

69 Boosting BCG with the ID93/GLA-SE vaccine significantly reduced b

70 n the lungs during murine pulmonary M. bovis BCG and M. tb.

71 urprisingly, 2 isolates belonged to M. bovis BCG group, which are not allowed for animal vaccination

72 CFU/ml compared to 143.4 CFU/ml for M. bovis BCG in humans.

73 arly steps of biofilm production in M. bovis BCG, to distinguish intercellular aggregation from attac

74 that M. tuberculosis and Mycobacterium bovis BCG are able to recycle components of their PG.

75 m spiked with 0 to 10(5) Mycobacterium bovis BCG cells/ml) underwent liquefaction in thermo-protectio

76 only available vaccine (Mycobacterium bovis BCG) protects children from disseminated forms of TB but

77 ouse model infected with Mycobacterium bovis BCG, as tested by real-time polymerase chain reaction.

78 hether vaccination with, Mycobacterium bovis BCG, has a similar effect.

79 the Rv2509 homologue in Mycobacterium bovis BCG, was unable to grow following the conditional deplet

80 lation on antigen-presenting cells (APCs) by BCG.

81 ; BCG and Tdap combined; or Tdap followed by BCG 3 months later.

82 73 log(10) CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost,

83 At 10(4) versus 10(3) cfu BCG, there was a significant increase in number of diffe

84 as halted, and the trial continued comparing BCG-Japan (3,191 neonates randomized, 3,184 analyzed) wi

85 as halted, and the trial continued comparing BCG-Japan (3191 neonates randomized, 3184 analyzed) with

86 In contrast, BCG stimulates long-term tumor-specific immunity that pr

87 t cytokines in both infections, they control BCG but not M. tb.

88 al TB vaccines in comparison to conventional BCG.

89 Corresponding BCG versus control case-fatality rate RRs were 0.58 (95%

90 entify differences between early and delayed BCG inoculation.

91 er BCG inoculation and the policy of delayed BCG inoculation was implemented since 2016, longer obser

92 6-week mortality did not differ: BCG-Denmark/BCG-Russia (MRR, 1.15 [95% CI, .74-1.80]); BCG-Japan/BCG

93 The 6-week mortality did not differ: BCG-Denmark/BCG-Russia (MRR, 1.15 [95% CI, .74-1.80]); B

94 dies indicate that the genetically divergent BCG strains have different effects.

95 GA and PCI (i.e., BCG) show weaker associations with clinical MS status th

96 als randomizing low-weight neonates to early BCG vaccination (intervention) versus no BCG vaccination

97 Despite these effects, BCG vaccination did not increase the rate of SIV oral tr

98 nistration increased tuberculosis deaths-eg, BCG vaccination at 6 weeks, the recommended age of DTP1,

99 , female, adult volunteers to receive either BCG, followed by a booster dose of tetanus-diphtheria-pe

100 vaccine would be co-administered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the seco

101 For BCG-Japan, there were 185 admissions vs 161 admissions f

102 spots vs. 5.0% for >=50 spots; and 3.1% for BCG-adjusted TST >=5 mm vs. 4.3% for >=15 mm).

103 =5 spots vs. 27.2% for >=50 spots; 69.7% for BCG-adjusted TST >=5 mm vs. 28.1% for >=15 mm).Conclusio

104 re were 185 admissions vs 161 admissions for BCG-Russia (IRR, 1.15 [95% CI, .93-1.43]).

105 ated with BCG-Denmark and 130 admissions for BCG-Russia, IRR=1.08 (95% Confidence Interval: 0.84-1.37

106 e-paracrine cytokine loop as a mechanism for BCG-mediated up-regulation of PD-L1.

107 The potential for BCG to provide protection against heterologous infection

108 helium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer.

109 ntigenic proteins that could be deleted from BCG without affecting the persistence and protective eff

110 Lower protection from BCG with increasing M. tuberculosis exposure and age can

111 try (GA) and bilateral coordination of gait (BCG), among pwMS during the six-minute walk test (6MWT),

112 censed TB vaccine, Bacillus Calmette-Guerin (BCG) against pulmonary TB.

113 l growth, including Bacille Calmette-Guerin (BCG) and Mycobacterium tuberculosis (MTB) Erdman.

114 on of live M. bovis Bacille Calmette-Guerin (BCG) and to observe interactions with each cell type, al

115 berculosis vaccine bacillus Calmette-Guerin (BCG) contributes to protection against heterologous infe

116 ycobacterium bovis bacillus Calmette-Guerin (BCG) cultures and TB-positive sputum samples, we show th

117 for tuberculosis, Bacillus Calmette-Guerin (BCG) has been suggested as a possible agent to prevent c

118 Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer is the only bacter

119 nogenicity of live bacillus Calmette-Guerin (BCG) in a lung-oriented controlled human infection model

120 Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for tuberculosis (TB),

121 birth with M. bovis bacille Calmette-Guerin (BCG) is widely used.

122 c administration of Bacille Calmette-Guerin (BCG) or beta-glucan reprograms HSCs in the bone marrow (

123 berculosis vaccine bacillus Calmette-Guerin (BCG) reduces overall infant mortality.

124 icacious TB vaccine bacille Calmette-Guerin (BCG) remain poorly defined.

125 ld age, absence of bacillus Calmette-Guerin (BCG) scar, presence of donor-specific antibody, and KTR

126 the inoculation of Bacillus Calmette-Guerin (BCG) Tokyo-172 strain vaccine was postponed from 24 hour

127 Bacillus Calmette-Guerin (BCG) vaccination induces variable protection against pul

128 n between national bacillus Calmette-Guerin (BCG) vaccination policy and the prevalence and mortality

129 Bacille Calmette-Guerin (BCG) vaccination remains a cornerstone against tuberculo

130 The Bacillus Calmette-Guerin (BCG) vaccine provides protection against tuberculosis (T

131 antigen-containing bacillus Calmette-Guerin (BCG) vaccine.

132 antigens and live bacillus Calmette-Guerin (BCG) were used as stimuli, with direct comparison to QFT

133 care immunotherapy, bacille Calmette-Guerin (BCG), constitute a challenging patient population to man

134 n vaccines, such as Bacille Calmette-Guerin (BCG), have nonspecific effects, which modulate innate im

135 erculosis vaccine, bacillus Calmette-Guerin (BCG), impacts early immunity is poorly understood.

136 in particular with Bacillus Calmette-Guerin (BCG), remain the main strategies to control TB.

137 Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, provides variable ef

138 ycobacterium bovis bacillus Calmette-Guerin (BCG), the only TB vaccine in common use, is effective ag

139 ted a recombinant Bacillus Calmette-Guerin ([BCG] BCG-disA-OE) that overexpresses the endogenous myco

140 justment for prior bacillus Calmette-Guerin [BCG] vaccination).Measurements and Main Results: For all

141 Heterologous BCG prime-boost regimens represent a promising strategy

142 scriminate vaccine responses in historically BCG-vaccinated human volunteers and to assess the contri

143 Understanding how BCG alters early immune responses to M. tuberculosis pro

144 tuberculosis deaths by 0.2% (0-0.4), even if BCG reached DTP1 coverage levels (94% at 3 years).

145 Importantly, BCG vaccination induced effector and memory cell differe

146 f the Th1 and Th17 cell lineages may improve BCG vaccine efficacy.

147 ates the functionality of a new and improved BCG strain which retains its protective efficacy but is

148 In BCG-vaccinated mice and guinea pigs, metformin enhances

149 Among 6583 infants (3297 in BCG group, 3286 controls), there were 908 infant hospita

150 /2 (Pam3CYSK4) stimulation were increased in BCG-vaccinated infants.

151 the spleen, bone marrow, and lung tissue in BCG-infected mice, whereas anti-TB therapy reduced IL-35

152 Compared to BCG-naive infants, BCG-vaccinated infants had increased production of inter

153 immunity may suggest increased inflammation, BCG vaccination has been epidemiologically associated wi

154 Interestingly, BCG infection could drive the infiltration of IL-35-prod

155 Interestingly, BCG-induced IFN-gamma expression by MAIT cells in vitro

156 ut of ten macaques that received intravenous BCG vaccination were highly protected, with six macaques

157 The finding that intravenous BCG prevents or substantially limits Mtb infection in hi

158 While intravesical BCG has remained the mainstay of therapy for intermediat

159 isk disease can be treated with intravesical BCG, but many of these patients will experience tumour r

160 ia (MRR, 1.15 [95% CI, .74-1.80]); BCG-Japan/BCG-Russia (MRR, 0.71 [95% CI, .43-1.19]).

161 tivated polio vaccine (Tdap) 3 months later; BCG and Tdap combined; or Tdap followed by BCG 3 months

162 BP waves in the limb BCG; and (iii) the limb BCG exhibits meaningful morphological changes in respons

163 athematical model suggests that (i) the limb BCG waveform reveals the timings and amplitudes associat

164 station of the arterial BP waves in the limb BCG; and (iii) the limb BCG exhibits meaningful morpholo

165 Live BCG, sterile PPD, and saline were bronchoscopically inst

166 controlled human infection model using live BCG and PPD is feasible and safe.

167 delivering a STING agonist from within live BCG.

168 Both sex and maternal BCG vaccination status influenced the effect of neonatal

169 BCG-Denmark and BCG-Japan induced more BCG scars and PPD reactions than BCG-Russia.

170 y outcome) and mortality while inducing more BCG reactions and purified protein derivative (PPD) resp

171 g subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, respectively, versus n

172 Furthermore, neonatal BCG programmes show the clearest proven benefit of vacci

173 ion status influenced the effect of neonatal BCG vaccination.

174 tatus of kidney transplantation, old age, no BCG vaccination, and positive donor-specific antibody ar

175 rly BCG vaccination (intervention) versus no BCG vaccination (usual practice in low-weight neonates,

176 e we show that intravenous administration of BCG profoundly alters the protective outcome of Mtb chal

177 evidence for a potential biological basis of BCG cross-protection from severe COVID-19, and refine th

178 ntly registered to inform on the benefits of BCG vaccinations upon exposure to CoV-2.

179 er BCG vaccination.CONCLUSIONThe capacity of BCG to enhance microbial responsiveness while dampening

180 Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and

181 ibe how diurnal rhythms affect the degree of BCG-induced innate memory.

182 copic resection and schedules of delivery of BCG.

183 Our findings support the development of BCG-vectored STING agonists as a tuberculosis vaccine st

184 ghout the day, we investigated the effect of BCG administration time on the induction of trained immu

185 ypothetical scenarios explored the effect of BCG delivery at birth, 6 weeks, 6 months, or 9-12 months

186 oluble, substrate of the circadian effect of BCG vaccination was demonstrated by the enhanced capacit

187 rtality, but a recent RCT found no effect of BCG-Russia.

188 rtality, but a recent RCT found no effect of BCG-Russia.

189 ate the nonspecific immunological effects of BCG and DTP-containing vaccines on the immune response t

190 The observed beneficial effects of BCG on the in-hospital mortality rate were entirely nons

191 Effects of BCG vaccination on hospitalization risk were assessed in

192 y also contributes to the anti-TB effects of BCG vaccination.

193 ficantly enhanced the protective efficacy of BCG against pulmonary and extrapulmonary tuberculosis.

194 nge model to test the protective efficacy of BCG-disA-OE versus wild-type BCG and measured lung weigh

195 ell responses does not alter the efficacy of BCG-induced tumor elimination.

196 at-treated and untreated (live) fractions of BCG and TB sputum samples for 42 days.

197 tly expanded peripheral blood frequencies of BCG-reactive IFN-gamma(+) MAIT cells, which returned to

198 Growth of BCG was reduced by 0.39, 0.96 and 0.73 log(10) CFU follo

199 iseases.METHODSWe investigated the impact of BCG (BCG-Bulgaria, InterVax) vaccination on systemic inf

200 However, the overall impact of BCG vaccination on the inflammatory status of an individ

201 cattle upon apical-basolateral migration of BCG was examined by quantifying recovered BCG from the a

202 ly morning should be the preferred moment of BCG administration.FUNDINGThe Netherlands Organization f

203 reactivity may explain disparate outcomes of BCG vaccination and susceptibility to TB disease.

204 cept experiments showed that the presence of BCG-specific Th cells in previously BCG-vaccinated mice

205 Clinical presentations of BCG-related adverse reactions reported to VICP for the 2

206 Halfway through the trial, production of BCG-Denmark was halted, and the trial continued comparin

207 Halfway through the trial, production of BCG-Denmark was halted, and the trial continued comparin

208 ll epitope of the secreted Ag 85B protein of BCG.

209 To assess the risk of BCG vaccination in HIV infection, we randomly assigned n

210 with a phenotype nearly identical to that of BCG, requiring a 200-fold higher concentration of hemin

211 Vaccine effectiveness (VE) of BCG, ascertained based on presence of a scar or vaccinat

212 protective boosting effect of ID93/GLA-SE on BCG-immunised animals.

213 aneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, respectively, versus naive mic

214 do not provide evidence to correlate overall BCG vaccination policy with the spread of CoV-2 and its

215 tion and heterologous boosting of parenteral BCG immunisation.

216 attenuated strain of the M. bovis pathogen, BCG, is not used to control bovine tuberculosis in cattl

217 ilm production and replication of planktonic BCG, whereas ethR affected only phenotypes linked to pla

218 Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed.

219 sence of BCG-specific Th cells in previously BCG-vaccinated mice had a dose-sparing effect for subseq

220 used to the Ag 85B epitope showed that prior BCG vaccination promoted high-affinity IgG1 responses th

221 ous for COVID-19 who did and did not receive BCG vaccination as part of routine childhood immunizatio

222 assigned newborn rhesus macaques to receive BCG vaccine or remain unvaccinated and then undergo oral

223 nother cohort of healthy adults who received BCG at birth, 53% of mycobacteria-reactive-activated CD8

224 e pulmonary TB (APTB) cases, and 24 recently BCG-vaccinated adolescents and naive controls.

225 vidence that mucosal delivery of recombinant BCG strains expressing the Mycobacterium tuberculosis (M

226 rkable anti-TB immunity by these recombinant BCG strains is achieved via augmenting the numbers and f

227 The numbers of recovered BCG in each fraction were unaffected by the presence of

228 of BCG was examined by quantifying recovered BCG from the apical, membrane and basolateral fractions

229 protein vaccines with the ability to recruit BCG-specific CD4(+) Th cells may be a useful and broadly

230 s used to prevent quantification of residual BCG from i.n. immunisation and allow accurate MTB quanti

231 r understanding of the effect of respiratory BCG vaccination on gammadelta T cell responses in the lu

232 used to assess trained immunity.RESULTSWhile BCG vaccination enhanced cytokine responses to restimula

233 We reviewed BCG-induced adverse reactions reported to Vaccine Injury

234 justing for other TB risk factors (age, sex, BCG-vaccination and stays >=3 months in Africa/Asia).

235 axillary lymph node, indicating significant BCG vaccine-induced immune activation.

236 rtially restored by concurrent or subsequent BCG vaccination.

237 contribute to growing evidence that suggests BCG may protect against M. tuberculosis infection as wel

238 m tuberculosis (Mtb) ESX-1 secretion system (BCG::RD1 and BCG::RD1 ESAT-6 Delta92-95) are safe and co

239 ince ID93/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we eval

240 When given together with Tdap or after Tdap, BCG abrogated the immunosuppressive effects of Tdap vacc

241 as more attenuated and more efficacious than BCG in a mouse model of infection.

242 ark and BCG-Japan were more immunogenic than BCG-Russia by the measures traditionally viewed as surro

243 egulatory factor 3, and IFN-beta levels than BCG-wild type (WT) in vitro in murine macrophages.

244 not had any previous vaccinations other than BCG, and oral polio vaccine.

245 nduced more BCG scars and PPD reactions than BCG-Russia.

246 ated strains more efficacious and safer than BCG.

247 We demonstrate that BCG therapy results in enhanced effector function of tum

248 ntrolled trials (RCTs) has demonstrated that BCG-Denmark lowers all-cause mortality, but a recent RCT

249 trolled trials (RCTs) have demonstrated that BCG-Denmark lowers all-cause mortality, but a recent RCT

250 152 high-burden countries, we estimated that BCG coverage in 2016 was 37% at 1 week of age, 67% at 6

251 In vivo in guinea pigs, we found that BCG-disA-OE reduced lung weights, pathology scores, and

252 ation but do not support the hypothesis that BCG vaccination is a risk factor for postnatal HIV trans

253 We hypothesized that BCG-Denmark would reduce morbidity (primary outcome) and

254 e JCI, Koeken and de Bree et al. report that BCG reduces circulating inflammatory markers in males bu

255 We have previously reported that BCG vaccination at birth alters in vitro cytokine respon

256 Herein we show that BCG-induced bladder tumor elimination requires CD4 and C

257 y, an in vivo immunisation model showed that BCG vaccination under PD-L1 blockade could enhance antig

258 ion and COVID-19 mortality, and suggest that BCG could have a protective effect.

259 A strong correlation between the BCG index, an estimation of the degree of universal BCG

260 Here we investigate delivery of both the BCG prime and adenovirus boost vaccination via the airwa

261 ), indicating that every 10% increase in the BCG index was associated with a 10.4% reduction in COVID

262 o include only patients strictly meeting the BCG-unresponsive definition.

263 e hampered disciplined interpretation of the BCG and systematic development of the BCG-based approach

264 of the BCG and systematic development of the BCG-based approaches for CV health monitoring.

265 opportunities toward next generation of the BCG-based CV healthcare techniques embedded with transpa

266 burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant protection

267 Healthy neonates were randomized 1:1 to BCG-Denmark (2,851 randomized, 2,840 analyzed) versus BC

268 Healthy neonates were randomized 1:1 to BCG-Denmark (2851 randomized, 2840 analyzed) vs BCG-Russ

269 Compared to BCG-naive infants, BCG-vaccinated infants had increased

270 use models of infection and is equivalent to BCG in a guinea pig model of infection.

271 f T1 bladder cancers and how they respond to BCG therapy could improve biomarkers for risk stratifica

272 using CD4(+) T cells arising in response to BCG as a source of help for driving Ab responses against

273 that influence the magnitude of responses to BCG and may be crucial to harnessing its potential benef

274 n maternal tribe, being born in a city/town, BCG scar and light Sm infection.

275 ive efficacy of BCG-disA-OE versus wild-type BCG and measured lung weights, pathology scores, and M.t

276 ex, an estimation of the degree of universal BCG vaccination deployment in a country, and COVID-19 mo

277 rity of COVID-19 in countries with universal BCG vaccination policies.

278 Here, we demonstrate that, unlike BCG or beta-glucan, Mtb reprograms HSCs via an IFN-I res

279 The only available vaccine, BCG (Bacillus Calmette-Guerin), is given intradermally a

280 rk (2,851 randomized, 2,840 analyzed) versus BCG-Russia (2,845 randomized, 2,837 analyzed).

281 -Denmark (2851 randomized, 2840 analyzed) vs BCG-Russia (2845 randomized, 2837 analyzed).

282 sue infection may occur less frequently when BCG is inoculated after 5 months of age, although mild a

283 We sought to determine whether BCG vaccination activated mycobacteria-specific MAIT cel

284 We explored whether BCG vaccination continues to be associated with decrease

285 91 neonates randomized, 3,184 analyzed) with BCG-Russia (3,170 randomized, 3,160 analyzed).

286 191 neonates randomized, 3184 analyzed) with BCG-Russia (3170 randomized, 3160 analyzed).

287 We found that infection of APCs with BCG induced PD-L1 up-regulation, but that this did not d

288 losis infection was strongly associated with BCG vaccination.

289 2.0 log10 CFU units (P < .05) compared with BCG-WT, respectively.

290 ules that involve giving the first dose with BCG and the second with DTP1 had the fewest excess intus

291 Infection with BCG was shown to exert a detrimental effect primarily up

292 ruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and

293 ourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

294 ed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

295 duals vaccinated between 8 am and 12 pm with BCG.RESULTSCompared with evening vaccination, morning va

296 th African adults who were revaccinated with BCG after a six-month course of isoniazid preventative t

297 HODSEighteen volunteers were vaccinated with BCG at 6 pm and compared with 36 age- and sex-matched vo

298 40 admissions among neonates vaccinated with BCG-Denmark and 130 admissions for BCG-Russia, IRR=1.08

299 30 admissions among neonates vaccinated with BCG-Denmark and BCG-Russia, respectively (IRR, 1.08 [95%

300 natal (28 days), 6-week, and infant (1-year) BCG versus control hospitalization IRRs were 0.97 (95% c